Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Fate Therapeutics Inc

FATE ✗ NOT COMPLIANT ☆ Track — members

Nasdaq · Healthcare · Biotechnology & Medical Research ·

USA Small Cap Analyst: BUY

Last Close

$2.57

▲ +1.98%

Market Cap $307.94M · Vol 314.40K

Key Metrics

P/E Ratio

N/A

FWD: N/A

Market Cap

$307.94M

Small Cap

Div Yield

N/A

EPS Growth

+5.94%

YoY

RSI (14)

55.56

Momentum

Beta

2.55

vs Market

52W High

$3.23

20.43% below

52W Low

$0.93

175.31% above

Volume

314.40K

Avg 540.78K

P/B

0.55

Price-to-book

ROE

-51.84%

Return on equity

Free Float

98.94%

Public shares

Shariah Compliance8 STANDARDS

✗ Fate Therapeutics Inc (FATE) stock is currently not Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does FATE pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-8.21%

-14.05%

+35.26%

+105.60%

YTD

+161.55%

+140.19%

-12.29%

-97.04%

Financials & Valuation

TTM · Annual

Total Revenue	$6.65M
Net Income	$-136,315,000.00
Revenue Growth (YoY)	+9.18%
Gross Margin	100.00%
Operating Margin	-2,222.45%
Net Profit Margin	-2,051.08%
ROE	-51.84%
ROA · ROIC	-35.89% · N/A

P/E Ratio	N/A
Forward P/E (FY1)	N/A
PEG Ratio	N/A
P/S	17.56
P/B	0.55
P/FCF	N/A
EPS Growth	+5.94%
Outstanding Shares	119.82M

Technical Indicators

50-Day SMA	$2.49
200-Day SMA	$1.62
RSI (14)	55.56
Beta	2.55
52-Week High	$3.23
52-Week Low	$0.93

Volume Today	314.40K
Avg Daily Volume (30D)	540.78K
Relative Volume	0.58x
Volatility (10D)	76.23
Volatility (30D)	68.09
Free Float	98.94%

Analyst Consensus

BUY

Current Price $2.57

Mean Target $5.74

52W Low$0.93 52W High$3.23

Current

Target

$0.93 $3.23

Current Analyst target

+123.52% upside potential · 12 analysts

Identifiers

ExchangeNasdaq

FIGIBBG001T888S2

ISINUS31189P1021

CountryUnited States of America

Sub-IndustryBio Therapeutic Drugs

Earnings DateNov 12, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -2.85% ARGX.BR argenx SE -3.21% ARGX argenx SE -0.66% INSM Insmed Inc -2.05% 2269.HK WuXi Biologics (Cayman) Inc -1.27%

Company Profile

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to bringing off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients. The Company's pipeline includes iPSC-derived, chimeric antigen receptor (CAR)-targeted T-cell and NK cell product candidates. The iPSC-derived T-cell and natural killer (NK) cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. The Company's product candidates under development include FT819, FT522, FT825, FT836, and others. FT819 is its first iPSC-derived CAR T-cell product candidate. FT825 is its first iPSC-derived CAR T-cell product candidate for the treatment of solid tumors being developed in collaboration with Ono Pharmaceutical. FT836 is the Company's multiplexed-engineered CAR T-cell product candidate targeting MHC proteins MICA and MICB.